Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Harpoon Therapeutics Inc (NQ: HARP ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Mar 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Harpoon Therapeutics Inc < Previous 1 2 Next > Harpoon Therapeutics Inc. (NASDAQ: HARP) Records 52-Week High Thursday Morning February 22, 2024 Via Investor Brand Network BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP) January 16, 2024 From Brodsky & Smith LLC Via GlobeNewswire HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP January 10, 2024 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP) January 08, 2024 From Brodsky & Smith LLC Via GlobeNewswire Harpoon Therapeutics Inc. (NASDAQ: HARP) Near the Top of Equities by Percentage Gain on 1/8 January 08, 2024 Via Investor Brand Network Merck, the Dow's hottest stock, gets set to report Q4 financials January 08, 2024 Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. Via MarketBeat Topics Stocks Exposures US Equities HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders January 08, 2024 From Halper Sadeh LLC Via Business Wire Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline January 08, 2024 From Merck & Co., Inc. Via Business Wire Harpoon Therapeutics Strengthens Leadership Team December 26, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium December 19, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D) December 11, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 09, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition November 02, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Announces Up to $150 Million Private Placement October 23, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 October 21, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Inc. (NASDAQ: HARP) Leading the Way in Wednesday Trading Based on Percentage Gain October 18, 2023 Via Investor Brand Network Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023 October 16, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 October 09, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting September 28, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort September 15, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie September 13, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting September 06, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023 September 05, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September September 05, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 09, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August August 03, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development August 01, 2023 From Harpoon Therapeutics Inc. Via GlobeNewswire Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma June 27, 2023 From Harpoon Therapeutics Via GlobeNewswire Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 11, 2023 From Harpoon Therapeutics Via GlobeNewswire Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023 April 18, 2023 From Harpoon Therapeutics Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
